207 related articles for article (PubMed ID: 22162542)
21. Cytochrome P450 3A and P-glycoprotein drug-drug interactions with voclosporin.
Ling SY; Huizinga RB; Mayo PR; Larouche R; Freitag DG; Aspeslet LJ; Foster RT
Br J Clin Pharmacol; 2014 Jun; 77(6):1039-50. PubMed ID: 24330024
[TBL] [Abstract][Full Text] [Related]
22. The effect of single- and multiple-dose etravirine on a drug cocktail of representative cytochrome P450 probes and digoxin in healthy subjects.
Kakuda TN; Van Solingen-Ristea RM; Onkelinx J; Stevens T; Aharchi F; De Smedt G; Peeters M; Leopold L; Hoetelmans RM
J Clin Pharmacol; 2014 Apr; 54(4):422-31. PubMed ID: 24165884
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes.
Walzer M; Bekersky I; Blum RA; Tolbert D
Pharmacotherapy; 2012 Apr; 32(4):340-53. PubMed ID: 22422635
[TBL] [Abstract][Full Text] [Related]
24. A pharmacokinetic drug-drug interaction study between selexipag and midazolam, a CYP3A4 substrate, in healthy male subjects.
Juif PE; Boehler M; Donazzolo Y; Bruderer S; Dingemanse J
Eur J Clin Pharmacol; 2017 Sep; 73(9):1121-1128. PubMed ID: 28639119
[TBL] [Abstract][Full Text] [Related]
25. Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity.
Kharasch ED; Walker A; Hoffer C; Sheffels P
J Clin Pharmacol; 2005 Oct; 45(10):1187-97. PubMed ID: 16172184
[TBL] [Abstract][Full Text] [Related]
26. PBPK modeling of CYP3A and P-gp substrates to predict drug-drug interactions in patients undergoing Roux-en-Y gastric bypass surgery.
Chen KF; Chan LN; Lin YS
J Pharmacokinet Pharmacodyn; 2020 Oct; 47(5):493-512. PubMed ID: 32710209
[TBL] [Abstract][Full Text] [Related]
27. The effects of multiple doses of rolofylline on the single-dose pharmacokinetics of midazolam in healthy subjects.
Stroh M; Dishy V; Radziszewski W; Hwang E; Lazarus-Shipitofsky N; Dittrich H; Johnson-Levonas AO; Lutz R; Wagner JA; Lai E
Am J Ther; 2010; 17(1):53-60. PubMed ID: 20027108
[TBL] [Abstract][Full Text] [Related]
28. Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam.
Chaobal HN; Kharasch ED
Clin Pharmacol Ther; 2005 Nov; 78(5):529-39. PubMed ID: 16321619
[TBL] [Abstract][Full Text] [Related]
29. Drug-Drug Interactions of the Nonsteroidal Mineralocorticoid Receptor Antagonist Apararenone With Midazolam, Warfarin, and Digoxin: A Phase 1 Studies in Healthy Volunteers.
Nakamura T; Shimizu H; Kawaguchi A
Clin Ther; 2020 Nov; 42(11):2171-2183.e4. PubMed ID: 33153727
[TBL] [Abstract][Full Text] [Related]
30. Effect of simultaneous induction and inhibition of CYP3A by St John's Wort and ritonavir on CYP3A activity.
Hafner V; Jäger M; Matthée AK; Ding R; Burhenne J; Haefeli WE; Mikus G
Clin Pharmacol Ther; 2010 Feb; 87(2):191-6. PubMed ID: 19924124
[TBL] [Abstract][Full Text] [Related]
31. Telaprevir: pharmacokinetics and drug interactions.
Garg V; Kauffman RS; Beaumont M; van Heeswijk RP
Antivir Ther; 2012; 17(7):1211-21. PubMed ID: 22954756
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers.
Hulskotte E; Gupta S; Xuan F; van Zutven M; O'Mara E; Feng HP; Wagner J; Butterton J
Hepatology; 2012 Nov; 56(5):1622-30. PubMed ID: 22576324
[TBL] [Abstract][Full Text] [Related]
33. A nanogram dose of the CYP3A probe substrate midazolam to evaluate drug interactions.
Halama B; Hohmann N; Burhenne J; Weiss J; Mikus G; Haefeli WE
Clin Pharmacol Ther; 2013 Jun; 93(6):564-71. PubMed ID: 23511711
[TBL] [Abstract][Full Text] [Related]
34. Reversible, time-dependent inhibition of CYP3A-mediated metabolism of midazolam and tacrolimus by telaprevir in human liver microsomes.
Chapron B; Risler L; Phillips B; Collins C; Thummel K; Shen D
J Pharm Pharm Sci; 2015; 18(1):101-11. PubMed ID: 25877445
[TBL] [Abstract][Full Text] [Related]
35. Effect of genistein on the activities of cytochrome P450 3A and P-glycoprotein in Chinese healthy participants.
Xiao CQ; Chen R; Lin J; Wang G; Chen Y; Tan ZR; Zhou HH
Xenobiotica; 2012 Feb; 42(2):173-8. PubMed ID: 21943317
[TBL] [Abstract][Full Text] [Related]
36. The Effect of GS-548351 on the Pharmacokinetics of Midazolam Following Multiple Doses of ANS-6637 in Healthy Adults.
Bunn HT; Rosenthal E; Mathur P; McLaughlin M; Proschan M; Vijan A; Aepfelbacher J; Kottilil S; Masur H; Kattakuzhy S; George JM
J Clin Pharmacol; 2020 Dec; 60(12):1598-1605. PubMed ID: 32578227
[TBL] [Abstract][Full Text] [Related]
37. Effects of omeprazole and ritonavir on absorption and elimination of the hepatitis C virus NS5A inhibitor GSK2336805 in healthy adults.
Adkison KK; Jones LS; Lou Y; Gan J; Wilfret DA
Clin Pharmacol Drug Dev; 2014 Sep; 3(5):338-45. PubMed ID: 27129005
[TBL] [Abstract][Full Text] [Related]
38. Effects of pregnancy on CYP3A and P-glycoprotein activities as measured by disposition of midazolam and digoxin: a University of Washington specialized center of research study.
Hebert MF; Easterling TR; Kirby B; Carr DB; Buchanan ML; Rutherford T; Thummel KE; Fishbein DP; Unadkat JD
Clin Pharmacol Ther; 2008 Aug; 84(2):248-53. PubMed ID: 18288078
[TBL] [Abstract][Full Text] [Related]
39. Effect of Telavancin on the pharmacokinetics of the cytochrome P450 3A probe substrate midazolam: a randomized, double-blind, crossover study in healthy subjects.
Wong SL; Goldberg MR; Ballow CH; Kitt MM; Barriere SL
Pharmacotherapy; 2010 Feb; 30(2):136-43. PubMed ID: 20099988
[TBL] [Abstract][Full Text] [Related]
40. Clarithromycin, Midazolam, and Digoxin: Application of PBPK Modeling to Gain New Insights into Drug-Drug Interactions and Co-medication Regimens.
Moj D; Hanke N; Britz H; Frechen S; Kanacher T; Wendl T; Haefeli WE; Lehr T
AAPS J; 2017 Jan; 19(1):298-312. PubMed ID: 27822600
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
